OBJECTIVES: This study sought to evaluate the relationship between platelet reactivity and atherosclerotic burden in patients undergoing percutaneous coronary intervention (PCI) with pre-intervention volumetric intravascular ultrasound (IVUS) imaging. BACKGROUND: Atherosclerosis progresses by the pathologic sequence of subclinical plaque rupture, thrombosis, and healing. In this setting, increased platelet reactivity may lead to more extensive arterial thrombosis at the time of plaque rupture, leading to a more rapid progression of the disease. Alternatively, abnormal vessel wall biology with advanced atherosclerosis is known to enhance platelet reactivity. Therefore, it is possible that by either mechanism, increased platelet reactivity may be associated with greater atherosclerotic burden. METHODS: This study included patients who underwent PCI with pre-intervention IVUS imaging and platelet reactivity functional assay (P2Y(12) reaction units) performed >16 h after PCI, after the stabilization of clopidogrel therapy (administered before PCI). Platelet reactivity >230 P2Y(12) reaction units defined high on-treatment platelet reactivity (HPR). RESULTS: Among 335 patients (mean age 65.0 years, 71% men), there were 109 patients with HPR (32.5%) and 226 without HPR (67.5%), with HPR being associated with diabetes and chronic renal insufficiency. By IVUS analysis, patients with HPR had significantly greater target lesion calcium lengths, calcium arcs, and calcium indexes. Furthermore, patients with HPR tended to have longer lesions and greater volumetric dimensions, indicating higher plaque volume, larger total vessel volume, and also greater luminal volume, despite similar plaque burden. By multivariate analysis controlling for baseline clinical variables, HPR was the single consistent predictor of all IVUS parameters examined, including plaque volume, calcium length, and calcium arc. CONCLUSIONS: Increased platelet reactivity on clopidogrel treatment, defined as >230 P2Y(12) reaction units, is associated with greater coronary artery atherosclerotic disease burden and plaque calcification.
OBJECTIVES: This study sought to evaluate the relationship between platelet reactivity and atherosclerotic burden in patients undergoing percutaneous coronary intervention (PCI) with pre-intervention volumetric intravascular ultrasound (IVUS) imaging. BACKGROUND:Atherosclerosis progresses by the pathologic sequence of subclinical plaque rupture, thrombosis, and healing. In this setting, increased platelet reactivity may lead to more extensive arterial thrombosis at the time of plaque rupture, leading to a more rapid progression of the disease. Alternatively, abnormal vessel wall biology with advanced atherosclerosis is known to enhance platelet reactivity. Therefore, it is possible that by either mechanism, increased platelet reactivity may be associated with greater atherosclerotic burden. METHODS: This study included patients who underwent PCI with pre-intervention IVUS imaging and platelet reactivity functional assay (P2Y(12) reaction units) performed >16 h after PCI, after the stabilization of clopidogrel therapy (administered before PCI). Platelet reactivity >230 P2Y(12) reaction units defined high on-treatment platelet reactivity (HPR). RESULTS: Among 335 patients (mean age 65.0 years, 71% men), there were 109 patients with HPR (32.5%) and 226 without HPR (67.5%), with HPR being associated with diabetes and chronic renal insufficiency. By IVUS analysis, patients with HPR had significantly greater target lesion calcium lengths, calcium arcs, and calcium indexes. Furthermore, patients with HPR tended to have longer lesions and greater volumetric dimensions, indicating higher plaque volume, larger total vessel volume, and also greater luminal volume, despite similar plaque burden. By multivariate analysis controlling for baseline clinical variables, HPR was the single consistent predictor of all IVUS parameters examined, including plaque volume, calcium length, and calcium arc. CONCLUSIONS: Increased platelet reactivity on clopidogrel treatment, defined as >230 P2Y(12) reaction units, is associated with greater coronary artery atherosclerotic disease burden and plaque calcification.
Authors: Yuqing Huo; Andreas Schober; S Bradley Forlow; David F Smith; Matthew Craig Hyman; Steffen Jung; Dan R Littman; Christian Weber; Klaus Ley Journal: Nat Med Date: 2002-12-16 Impact factor: 53.440
Authors: Stephanie Pitsilos; Jennifer Hunt; Emile R Mohler; Anand M Prabhakar; Mortimer Poncz; Jennine Dawicki; Tigran Z Khalapyan; Megan L Wolfe; Ronald Fairman; Marc Mitchell; Jeffrey Carpenter; Michael A Golden; Douglas B Cines; Bruce S Sachais Journal: Thromb Haemost Date: 2003-12 Impact factor: 5.249
Authors: A Jaberi; C Lum; P Stefanski; R Thornhill; D Iancu; W Petrcich; F Momoli; C Torres; D Dowlatshahi Journal: Neuroradiology Date: 2013-11-10 Impact factor: 2.804
Authors: Prasad G Jamkhande; Prakash G Chandak; Shashikant C Dhawale; Sonal R Barde; Priti S Tidke; Ram S Sakhare Journal: Saudi Pharm J Date: 2013-11-05 Impact factor: 4.330
Authors: George D Dangas; Akiko Maehara; Solene M Evrard; Samantha Sartori; Jennifer R Li; Amala P Chirumamilla; Aya Nomura-Kitabayashi; Nilusha Gukathasan; Ahmed Hassanin; Usman Baber; Martin Fahy; Valentin Fuster; Gary S Mintz; Jason C Kovacic Journal: Eur Heart J Cardiovasc Imaging Date: 2013-07-31 Impact factor: 6.875
Authors: Wouter J Kikkert; Bimmer E Claessen; Gregg W Stone; Roxana Mehran; Bernhard Witzenbichler; Bruce R Brodie; Jochen Wöhrle; Adam Witkowski; Giulio Guagliumi; Krzysztof Zmudka; José P S Henriques; Jan G P Tijssen; Elias A Sanidas; Vasiliki Chantziara; Ke Xu; George D Dangas Journal: J Thromb Thrombolysis Date: 2014 Impact factor: 2.300
Authors: Bo Rong Zhou; Hong Ting Shi; Rong Wang; Min Zhang; Hai Tao Guan; Zi Fan Liu; Yan Hua Deng Journal: J Neurol Date: 2013-10-18 Impact factor: 4.849